ATE322544T1 - Hybrider faktor viii aus sequenzen von mensch und schwein - Google Patents

Hybrider faktor viii aus sequenzen von mensch und schwein

Info

Publication number
ATE322544T1
ATE322544T1 AT03075987T AT03075987T ATE322544T1 AT E322544 T1 ATE322544 T1 AT E322544T1 AT 03075987 T AT03075987 T AT 03075987T AT 03075987 T AT03075987 T AT 03075987T AT E322544 T1 ATE322544 T1 AT E322544T1
Authority
AT
Austria
Prior art keywords
factor viii
pig
sequences
human
hybrid factor
Prior art date
Application number
AT03075987T
Other languages
English (en)
Inventor
John S Lollar
Marschall S Runge
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25342308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE322544(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of ATE322544T1 publication Critical patent/ATE322544T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrotherapy Devices (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03075987T 1992-04-07 1993-04-07 Hybrider faktor viii aus sequenzen von mensch und schwein ATE322544T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/864,004 US5364771A (en) 1992-04-07 1992-04-07 Hybrid human/porcine factor VIII

Publications (1)

Publication Number Publication Date
ATE322544T1 true ATE322544T1 (de) 2006-04-15

Family

ID=25342308

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03075987T ATE322544T1 (de) 1992-04-07 1993-04-07 Hybrider faktor viii aus sequenzen von mensch und schwein
AT93912141T ATE284963T1 (de) 1992-04-07 1993-04-07 Hybrider menschlich-schweinlicher faktor viii

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT93912141T ATE284963T1 (de) 1992-04-07 1993-04-07 Hybrider menschlich-schweinlicher faktor viii

Country Status (11)

Country Link
US (2) US5364771A (de)
EP (2) EP1359222B1 (de)
JP (2) JP3440097B2 (de)
AT (2) ATE322544T1 (de)
AU (1) AU682147B2 (de)
CA (1) CA2133203C (de)
DE (2) DE69334003T2 (de)
DK (2) DK0638088T3 (de)
ES (2) ES2235154T3 (de)
PT (1) PT1359222E (de)
WO (1) WO1993020093A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5859204A (en) * 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
HK1039059A1 (zh) 1998-09-21 2002-04-12 Genetics Institute, Llc 负调节对治疗蛋白的免疫应答的方法
DK1129186T4 (da) † 1998-11-10 2017-02-06 Stichting Sanquin Bloedvoorziening Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
US7615622B2 (en) * 2001-01-12 2009-11-10 University Of Maryland, Baltimore Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
EP1421539B1 (de) 2001-06-14 2009-10-28 The Scripps Research Institute Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
EP1572885A2 (de) * 2001-08-08 2005-09-14 Genzyme Corporation Verfahren zur behandlung von diabetes und anderer blutzuckerstörungen
US20040143104A1 (en) * 2001-08-08 2004-07-22 Wadsworth Samuel C. Methods of treating diabetes and other blood sugar disorders
DE60230456D1 (de) 2001-10-05 2009-01-29 Expression Therapeutics Llc Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
US20040249134A1 (en) * 2001-11-30 2004-12-09 Lollar John S. Factor viii c2 domain variants
US20050123997A1 (en) * 2003-10-30 2005-06-09 Lollar John S. Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
US7211559B2 (en) * 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
US20050107318A1 (en) * 2003-11-17 2005-05-19 Samuel Wadsworth Methods of treating diabetes and other blood sugar disorders
PL1750733T3 (pl) * 2004-05-03 2014-05-30 Univ Emory Sposób podawania świńskiego czynnika krzepnięcia VIII pozbawionego domeny B
JP2008512098A (ja) 2004-09-07 2008-04-24 アーケミックス コーポレイション フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
AU2005282380A1 (en) 2004-09-07 2006-03-16 Archemix Corp. Aptamer medicinal chemistry
US20060080848A1 (en) * 2004-10-19 2006-04-20 Lace Charles R Wheel blade sight
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
KR20080007226A (ko) * 2005-04-14 2008-01-17 체에스엘 베링 게엠베하 증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체
EP1816201A1 (de) * 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
ATE474917T1 (de) * 2006-04-11 2010-08-15 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
EP1935430A1 (de) * 2006-12-22 2008-06-25 CSL Behring GmbH Veränderte Koagulationsfaktoren mit verlängerter in vivo Halbwertzeit
WO2008077616A1 (en) * 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
FR2913020B1 (fr) * 2007-02-23 2012-11-23 Biomethodes Nouveaux facteurs viii pour le traitement des hemophiles de type a
EP2865760B1 (de) 2008-06-24 2017-10-11 CSL Behring GmbH Faktor viii, von-willebrand-faktor oder komplexe davon mit verlängerter in-vivo-halbwertzeit
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
RU2579977C2 (ru) 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ
EP4382170A3 (de) 2009-12-06 2024-09-04 Bioverativ Therapeutics Inc. Chimäre und hybride faktor-viii-fc-polypeptide und verfahren zur verwendung davon
US20110177107A1 (en) * 2010-01-14 2011-07-21 Haplomics, Inc. Predicting and reducing alloimmunogenicity of protein therapeutics
WO2011127426A1 (en) * 2010-04-08 2011-10-13 Baxter International Inc. Methods for modeling protein stability
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
BR112013011041B1 (pt) 2010-11-05 2021-05-25 Baxalta GmbH variante de fator viii, método para produzir uma variante de fviii, uso da variante de fator viii, e, composição farmacêutica
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
EP4169525A1 (de) 2011-07-08 2023-04-26 Bioverativ Therapeutics Inc. Chimäre und hybride faktor-viii-polypeptide und verfahren zur verwendung davon
EA028914B1 (ru) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Исследования для мониторинга нарушений свертываемости крови
HRP20191920T1 (hr) 2012-01-12 2020-01-10 Bioverativ Therapeutics Inc. Kimerni polipeptidi faktora viii i njihova uporaba
EA038705B1 (ru) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Способы снижения иммуногенности фактора свёртывания крови viii у пациентов, получающих лечение фактором viii
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
ES2770501T3 (es) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
WO2014070953A1 (en) 2012-10-30 2014-05-08 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
ES2926798T3 (es) 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
EP2796145B1 (de) 2013-04-22 2017-11-01 CSL Ltd. Ein kovalenter komplex bestehend aus von willebrand und faktor viii verbunden mit einer disulfidbrücke
HRP20210031T1 (hr) 2013-06-24 2021-05-14 Weidong, Xiao Pripravci i metode mutantskog faktora viii
KR20230007555A (ko) 2013-06-28 2023-01-12 바이오버라티브 테라퓨틱스 인크. Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
EP3875106A1 (de) 2013-08-08 2021-09-08 Bioverativ Therapeutics Inc. Reinigung von chimären fviii-molekülen
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE32011E (en) * 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
MX9203440A (es) * 1985-04-12 1992-07-01 Genetics Inst Proteinas procoagulantes novedosas.
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
US5004803A (en) * 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5246850A (en) * 1990-07-31 1993-09-21 Genentech, Inc. DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells
SE468050C (sv) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
US5563045A (en) * 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins

Also Published As

Publication number Publication date
PT1359222E (pt) 2006-07-31
DE69333724D1 (de) 2005-01-20
HK1058946A1 (en) 2004-06-11
AU4279993A (en) 1993-11-08
EP0638088B1 (de) 2004-12-15
JP3440097B2 (ja) 2003-08-25
EP0638088A4 (de) 1996-06-26
JP3495365B2 (ja) 2004-02-09
US5583209A (en) 1996-12-10
US5364771A (en) 1994-11-15
ES2235154T3 (es) 2005-07-01
JPH07508404A (ja) 1995-09-21
EP0638088A1 (de) 1995-02-15
AU682147B2 (en) 1997-09-25
DE69333724T2 (de) 2005-11-10
DK0638088T3 (da) 2005-04-25
WO1993020093A1 (en) 1993-10-14
EP1359222A3 (de) 2003-11-19
EP1359222A2 (de) 2003-11-05
CA2133203A1 (en) 1993-10-14
ES2261866T3 (es) 2006-11-16
ATE284963T1 (de) 2005-01-15
DE69334003D1 (de) 2006-05-18
JP2003174876A (ja) 2003-06-24
DK1359222T3 (da) 2006-06-19
DE69334003T2 (de) 2007-01-25
EP1359222B1 (de) 2006-04-05
CA2133203C (en) 2002-07-02

Similar Documents

Publication Publication Date Title
DE69334003D1 (de) Hybrider Faktor VIII aus Sequenzen von Mensch und Schwein
DK0672138T3 (da) Kimære prokoagulante proteiner
DE69736068D1 (de) Faktor viii vom schwein und hybriden
DE69416492D1 (de) Härtungskontrolle von Silikongummizusammensetzungen
DE69328758D1 (de) Verfahren zur Herstellung von SOI-Bipolar- und MOS-Transistoren
DE69223027D1 (de) Verfahren und Klebstoff zur Herstellung von elektrischen und mechanischen Verbindungen
DE69304368D1 (de) IC-gesteuerter Gleichstrommotor
DE69408551D1 (de) Verfahren zur Herstellung von bemaltem Silikon-Elastomer
DE69312853D1 (de) Behandlung von Gummiartikeln
DE69320059D1 (de) Verfahren zur herstellung von 1,1,1,4,4,4-hexafluoro-2-buten und 1,1,1,4,4,4-hexafluorobutan
DE59302386D1 (de) Verwendung von polykondensaten und neue polykondensate
DE69327164D1 (de) Spannungserhöhungsschaltung zur Erzeugung von positiven und negativen erhöhten Spannungen
DE69311183D1 (de) Verfahren zur Herstellung von Acryloxy- oder Methacryloxygruppen enthaltenden Organosiliconen
DE59304719D1 (de) Verfahren zur Herstellung von Polysilazanen
DE69225702D1 (de) Verfahren zur Herstellung von kompakten Reinigungsmitteln
DE69206961D1 (de) Verfahren zur Dehydrierung von Kohlenwasserstoffen und von sauerstoffenthaltenden Kohlenwasserstoffen
DE69432507D1 (de) Verfahren und Geräte zur Erzeugung von Zeichnungsdaten
DE69317180D1 (de) Verfahren zur Herstellung von IC-Karten
DE69325452D1 (de) Verfahren zur herstellung von (s)-3-amino-1-substituiert-pirrolidine
DE69321848D1 (de) Verfahren zur herstellung von 1,1,1,2,3,3-hexafluorpropan und von tetrafluorchlorpropen
DE59106383D1 (de) Verfahren und einrichtung zur oxidation von wasserstoff.
DE69400342D1 (de) Verfahren zur Herstellung von 1,1,1,2-Tetrafluor-2-Chlorethan und Pentafluorethan
DE69314445D1 (de) Verfahren zur Herstellung von Wasserstoffperoxyd
DE59101473D1 (de) Verfahren zur Herstellung von N-aryl-substituierten 2-Aminoalkyl-2-hydroxy-alkylaminen und N-arylsubstituierten Piperazinen.
DE59209120D1 (de) Mittel zur Härtung von hornartigen Körperteilen von Säugetieren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties